AzTrials
AzTrials

ArthritisPhase 3NCT00830063

Tanezumab In Osteoarthritis Of The Knee (2)

A Phase 3 study testing tanezumab 10 mg, tanezumab 5 mg and naproxen in people with Arthritis and Osteoarthritis, run by Pfizer at 94 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to test the efficacy and safety of 2 doses of tanezumab compared with naproxen and placebo in patients with osteoarthritis. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Arthritis, Osteoarthritis
What is being tested?
tanezumab 10 mg, tanezumab 5 mg and naproxen
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
832 participants
Where
94 sitesUnited States
Study dates
5 May 2009to 31 Aug 2010
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Osteoarthritis of the knee according to Kellgren-Lawrence x-ray grade of 2

Who cannot join

  • Pregnancy or intent to become pregnant
  • BMI greater than 39
  • other severe pain, significant cardiac, neurologic or cardiac disease

Trial locations and contacts

94 sites in 1 country.

94 sites in 1 country

United States94 sites
  • Albuquerque Clinical Trials, Inc.

    Albuquerque, New Mexico, 87102

  • New Mexico Clinical Research & Osteoporosis Center, Incorporated

    Albuquerque, New Mexico, 87106

  • McFarland Clinic, PC

    Ames, Iowa, 50010

  • Anniston Medical Clinic, PC

    Anniston, Alabama, 36207

  • Pinnaccle Research Group, LLC

    Anniston, Alabama, 36207

  • Arthritis and Rheumatology of Georgia

    Atlanta, Georgia, 30342

  • Maine Research Associates

    Auburn, Maine, 04210

  • Capitol Medical Clinic

    Austin, Texas, 78705

  • Office of Walter F Chase, MD, PA

    Austin, Texas, 78705

  • Stanocola Medical Center

    Baton Rouge, Louisiana, 70816

  • Comprehensive Clinical Research

    Berlin, New Jersey, 08009

  • Osteoporosis Medical Center

    Beverly Hills, California, 90211

  • Sonora Clinical Research

    Boise, Idaho, 83702

  • Carolina Bone and Joint, PA

    Charlotte, North Carolina, 28210

  • Rehabilitation Institute of Chicago

    Chicago, Illinois, 60611

  • Hightop Medical Research Center

    Cincinnati, Ohio, 45224

  • Hilltop Physicians Inc / Hightop Medical Research Center

    Cincinnati, Ohio, 45224

  • Innovative Research of West Florida, Inc

    Clearwater, Florida, 33756

  • Tampa Bay Medical Research, Inc.

    Clearwater, Florida, 33761

  • Clinical Research of South Florida

    Coral Gables, Florida, 33134

  • North Texas Joint Care, PA

    Dallas, Texas, 75230

  • Jeffrey D. Lieberman, MD

    Decatur, Georgia, 30033

  • Avail Clinical Research, LLC

    DeLand, Florida, 32720

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania, 16635

  • MAPS Applied Research Center, Inc

    Edina, Minnesota, 55435

  • Medical Advanced Pain Specialists

    Edina, Minnesota, 55435

  • Odyssey Research

    Fargo, North Dakota, 58104

  • Plains Medical Clinic, LLC

    Fargo, North Dakota, 58104

  • Arthritis and Osteoporosis Center of Maryland

    Frederick, Maryland, 21702

  • Valley Research

    Fresno, California, 93720

  • Pharmquest

    Greensboro, North Carolina, 27408

  • St. Joseph's Mercy Clinic

    Hot Springs, Arkansas, 71913

  • Asif Cochinwala, MD, PA

    Houston, Texas, 77008

  • Pioneer Research Solutions, Inc

    Houston, Texas, 77036

  • Talbert Medical Group

    Huntington Beach, California, 92646

  • Westside Center for Clinical Research

    Jacksonville, Florida, 32205

  • Appalachian Medical Research, Inc

    Johnson City, Tennessee, 37604

  • Holston Medical Group

    Kingsport, Tennessee, 37660

  • Clinical Research Consortium

    Las Vegas, Nevada, 89119

  • Mirkil Medical

    Las Vegas, Nevada, 89119

  • G. Timothy Kelly, MD

    Las Vegas, Nevada, 89128

  • Michael Clifford, MD

    Las Vegas, Nevada, 89128

  • Adult Medicine Specialists

    Longwood, Florida, 32779

  • Genesis Research International

    Longwood, Florida, 32779

  • David H. Neustadt, PSC

    Louisville, Kentucky, 40202

  • Marietta Rheumatology

    Marietta, Georgia, 30060

  • Clinical Research Advantage, Inc. / Mesa Family Medical Center, PC

    Mesa, Arizona, 85203

  • Kendall South Medical Center, Inc

    Miami, Florida, 33175

  • Southwest Rheumatology and Research Group, LLC

    Middleburg Heights, Ohio, 44130

  • Koch Family Practice

    Morton, Illinois, 61550

  • Illinois Bone and Joint Institute, LLC

    Morton Grove, Illinois, 60053

  • Coastal Carolina Research Center

    Mt. Pleasant, South Carolina, 29464

  • The Medical Research Network, LLC

    New York, New York, 10024

  • Javed Rheumatology Associates, Inc.

    Newark, Delaware, 19713

  • National Clinical Research - Norfolk, Inc.

    Norfolk, Virginia, 23502

  • Health Research Institute

    Oklahoma City, Oklahoma, 73109

  • Quality Clinical Research, Inc.

    Omaha, Nebraska, 68114

  • Aspen Clinical Research, LLC

    Orem, Utah, 84058

  • The Arthritis Center

    Palm Harbor, Florida, 34684

  • Arizona Arthritis & Rheumatology Associates, P.C.

    Paradise Valley, Arizona, 85253

  • University Clinical Research, Inc.

    Pembroke Pines, Florida, 33024

  • Pivotal Research Centers

    Peoria, Arizona, 85381

  • Arizona Research Center

    Phoenix, Arizona, 85023

  • Arizona Arthritis & Rheumatology Associates, P.C.

    Phoenix, Arizona, 85037

  • Progressive Medical Research

    Port Orange, Florida, 32127

  • Arthritis and Rheumatic Diseases

    Portsmouth, Virginia, 23701

  • Health Concepts

    Rapid City, South Dakota, 57702

  • AAIR Research Center

    Rochester, New York, 14618

  • Andrew J. Porges, MD, PC

    Roslyn, New York, 11576

  • UC Davis Medical Center

    Sacramento, California, 95817

  • Shores Rheumatology, P.C.

    Saint Clair Shores, Michigan, 48081

  • Radiant Research San Antonio Northeast

    San Antonio, Texas, 78217

  • Diagnostic Research Group

    San Antonio, Texas, 78229

  • Diagnostics Research Group

    San Antonio, Texas, 78229

  • South Texas Radiology Group

    San Antonio, Texas, 78229

  • The Arthritis Center

    Springfield, Illinois, 62704

  • Mercy Health Research

    St Louis, Missouri, 63141

  • Stamford Therapeutics Consortium

    Stamford, Connecticut, 06905

  • West Broward Rheumatology Associates, Inc.

    Tamarac, Florida, 33321

  • Lawrence P McAdam, MD / A Medical Corporation

    Thousand Oaks, California, 91360

  • University of Arizona - Arizona Arthritis Center

    Tucson, Arizona, 85724

  • University of Arizona

    Tucson, Arizona, 85724

  • Northwest Indiana Center for Clinical Research

    Valparaiso, Indiana, 46383

  • Integrated Clinical Trial Services, Inc.

    West Des Moines, Iowa, 50265

  • Palm Beach Research Center

    West Palm Beach, Florida, 33409

  • Clinical Research Center of Reading, LLP

    West Reading, Pennsylvania, 19611

  • The Center for Rheumatology and Bone Research

    Wheaton, Maryland, 20902

  • Professional Research Network of Kansas, LLC

    Wichita, Kansas, 67203

  • Physician Pain Care

    Woodstock, Georgia, 30188

  • North Georgia Clinical Research

    Woodstock, Georgia, 30189

  • North Georgia Internal Medicine

    Woodstock, Georgia, 30189

  • Clinical Pharmacology Study Group

    Worcester, Massachusetts, 01610

  • Clinical Trials Northwest

    Yakima, Washington, 98902

  • Pharmacotherapy Research Associates Incorporated

    Zanesville, Ohio, 43701

Other trials in United States

About this study

Official title: A PHASE 3 RANDOMIZED, DOUBLE BLIND PLACEBO AND NAPROXEN CONTROLLED MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE

The purpose of this study is to test the efficacy and safety of 2 doses of tanezumab compared with naproxen and placebo in patients with osteoarthritis.

Being tested
tanezumab 10 mg, tanezumab 5 mg, naproxen, placebo
Keywords
monoclonal antibody, RN624, PF-04383119, nerve growth factor, anti-nerve growth factor, OA, pain
Medical subject headings
Arthritis, Osteoarthritis, Hereditary Sensory and Autonomic Neuropathies, Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • tanezumab 10 mgBiological

    tanezumab 10 mg one dose at weeks 0 and 8

  • tanezumab 5 mgBiological

    tanezumab 5 mg one dose at weeks 0 and 8

  • naproxenDrug

    naproxen 1000 mg daily for 16 weeks

  • placeboOther

    placebo to match tanezumab and naproxen dosing

Study groups in NCT00830063
Study groupRoleWhat they receive
1ExperimentalNot described
Receives: Biological: tanezumab 10 mg
2ExperimentalNot described
Receives: Biological: tanezumab 5 mg
3Active comparatorNot described
Receives: Drug: naproxen
4Placebo comparatorNot described
Receives: Other: placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 16: Baseline Observation Carried Forward (BOCF)

    WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms in participants with osteoarthritis of knee. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in the index knee during past 48 hours. It is calculated as mean of the scores from 5 individual questions scored on a numerical rating scale of 0 (minimum pain) to 10 (maximum pain), where higher scores indicate more pain. An overall possible WOMAC pain subscale score range is of 0 (minimum pain) to 10 (maximum pain), where higher scores indicate more pain.

    Measured: Baseline (Day 1), Week 16

  2. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Week 16: Baseline Observation Carried Forward (BOCF)

    WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms in participants with osteoarthritis of knee. WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index knee joint during past 48 hours. It is calculated as mean of the scores from 17 individual questions scored on a numerical rating scale of 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicate more difficulty. An overall possible WOMAC physical function subscale score range is of 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicate worse function. Physical function refers to participant's ability to move around and perform usual activities of daily living.

    Measured: Baseline, Week 16

  3. Change From Baseline in Patient Global Assessment of Osteoarthritis at Week 16: Baseline Observation Carried Forward (BOCF)

    Participants answered: "Considering all the ways the osteoarthritis in your index knee affects you, how are you doing today?" Participants responded on the scale ranging from 1 (minimum affected) to 5 (maximum affected), where 1= very good, 2= good, 3= fair, 4= poor and 5= very poor. Higher scores indicate worse condition.

    Measured: Baseline, Week 16

Secondary outcomes (30)
  1. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 2, 4, 8 and 12: Baseline Observation Carried Forward (BOCF)

    WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms in participants with osteoarthritis of knee. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in the index knee during past 48 hours. It is calculated as mean of the scores from 5 individual questions scored on a numerical rating scale of 0 (minimum pain) to 10 (maximum pain), where higher scores indicate more pain. An overall possible WOMAC pain subscale score range is of 0 (minimum pain) to 10 (maximum pain), where higher scores indicate more pain.

    Measured: Baseline, Week 2, 4, 8, 12

  2. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 2, 4, 8 and 12: Last Observation Carried Forward (LOCF)

    WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms in participants with osteoarthritis of knee. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in the index knee during past 48 hours. It is calculated as mean of the scores from 5 individual questions scored on a numerical rating scale of 0 (minimum pain) to 10 (maximum pain), where higher scores indicate more pain. An overall possible WOMAC pain subscale score range is of 0 (minimum pain) to 10 (maximum pain), where higher scores indicate more pain.

    Measured: Baseline, Week 2, 4, 8, 12

  3. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Week 2, 4, 8 and 12: Baseline Observation Carried Forward (BOCF)

    WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms in participants with osteoarthritis of knee. WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index knee joint during past 48 hours. It is calculated as mean of the scores from 17 individual questions scored on a numerical rating scale of 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicate more difficulty. An overall possible WOMAC physical function subscale score range is of 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicate worse function. Physical function refers to participant's ability to move around and perform usual activities of daily living.

    Measured: Baseline, Week 2, 4, 8, 12

  4. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Week 2, 4, 8 and 12: Last Observation Carried Forward (LOCF)

    WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms in participants with osteoarthritis of knee. WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index knee joint during past 48 hours. It is calculated as mean of the scores from 17 individual questions scored on a numerical rating scale of 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicate more difficulty. An overall possible WOMAC physical function subscale score range is of 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicate worse function. Physical function refers to participant's ability to move around and perform usual activities of daily living.

    Measured: Baseline, Week 2, 4, 8, 12

  5. Change From Baseline in Patient Global Assessment of Osteoarthritis at Week 2, 4, 8 and 12: Baseline Observation Carried Forward (BOCF)

    Participants answered: "Considering all the ways the osteoarthritis in your index knee affects you, how are you doing today?" Participants responded on the scale ranging from 1 (minimum affected) to 5 (maximum affected), where 1= very good, 2= good, 3= fair, 4= poor and 5= very poor. Higher scores indicate worse condition.

    Measured: Baseline, Week 2, 4, 8, 12

  6. Change From Baseline in Patient Global Assessment of Osteoarthritis at Week 2, 4, 8 and 12: Last Observation Carried Forward (LOCF)

    Participants answered: "Considering all the ways the osteoarthritis in your index knee affects you, how are you doing today?" Participants responded on the scale ranging from 1 (minimum affected) to 5 (maximum affected), where 1= very good, 2= good, 3= fair, 4= poor and 5= very poor. Higher scores indicate worse condition.

    Measured: Baseline, Week 2, 4, 8, 12

  7. Percentage of Responders For Outcome Measures in Rheumatology- Osteoarthritis Research Society International (OMERACT-OARSI): Baseline Observation Carried Forward (BOCF)

    A participant was considered as an OMERACT-OARSI responder: if the improvement from baseline to week of interest was greater than or equal to (>=) 50 percent and >=2 units in WOMAC pain or physical function subscale; if improvement from baseline to week of interest was >=20 percent and >=1 unit in at least 2 of the following: a) WOMAC pain subscale, b) WOMAC physical function subscale, c) PGA of osteoarthritis. WOMAC pain subscale assess amount of pain experienced (score: 0 [minimum pain] to 10 [maximum pain], higher score = more pain), WOMAC physical function subscale assess degree of difficulty experienced (score: 0 [minimum difficulty] to 10 [maximum difficulty], higher score = higher difficulty) and PGA of osteoarthritis (score: 1 [minimum affected] to 5 [maximum affected], higher score = worse condition). Percentage of participants who were OMERACT-OARSI responder were reported in this outcome measure.

    Measured: Weeks 2, 4, 8, 12, 16

  8. Percentage of Responders For Outcome Measures in Rheumatology- Osteoarthritis Research Society International (OMERACT-OARSI): Last Observation Carried Forward (LOCF)

    A participant was considered as an OMERACT-OARSI responder: if the improvement from baseline to week of interest was greater than or equal to (>=) 50 percent and >=2 units in WOMAC pain or physical function subscale; if improvement from baseline to week of interest was >=20 percent and >=1 unit in at least 2 of the following: a) WOMAC pain subscale, b) WOMAC physical function subscale, c) PGA of osteoarthritis. WOMAC pain subscale assess amount of pain experienced (score: 0 [minimum pain] to 10 [maximum pain], higher score = more pain), WOMAC physical function subscale assess degree of difficulty experienced (score: 0 [minimum difficulty] to 10 [maximum difficulty], higher score = higher difficulty) and PGA of osteoarthritis (score: 1 [minimum affected] to 5 [maximum affected], higher score = worse condition). Percentage of participants who were OMERACT-OARSI responder were reported in this outcome measure.

    Measured: Week 2, 4, 8, 12, 16

  9. Percentage of Participants With at Least 30 Percent, and 50 Percent Reduction in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale: Baseline Observation Carried Forward (BOCF)

    WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms in participants with osteoarthritis of knee. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in the index knee during past 48 hours. It is calculated as mean of the scores from 5 individual questions scored on a numerical rating scale of 0 (minimum pain) to 10 (maximum pain), where higher scores indicate more pain. An overall possible WOMAC pain subscale score range is of 0 (minimum pain) to 10 (maximum pain), where higher scores indicate more pain. Percentage of participants with at least 30 percent and 50 percent reduction in WOMAC pain subscale were reported in this outcome measure.

    Measured: Week 2, 4, 8, 12, 16

  10. Percentage of Participants With at Least 30 Percent, and 50 Percent Reduction in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale: Last Observation Carried Forward (LOCF)

    WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms in participants with osteoarthritis of knee. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in the index knee during past 48 hours. It is calculated as mean of the scores from 5 individual questions scored on a numerical rating scale of 0 (minimum pain) to 10 (maximum pain), where higher scores indicate more pain. An overall possible WOMAC pain subscale score range is of 0 (minimum pain) to 10 (maximum pain), where higher scores indicate more pain. Percentage of participants with at least 30 percent and 50 percent reduction in WOMAC pain subscale were reported in this outcome measure.

    Measured: Week 2, 4, 8, 12, 16

  11. Percentage of Participants With at Least 2 Points Improvement From Baseline in Patient Global Assessment (PGA) of Osteoarthritis: Baseline Observation Carried Forward (BOCF)

    Participants answered: "Considering all the ways the osteoarthritis in your index knee affects you, how are you doing today?" Participants responded on the scale ranging from 1 (minimum affected) to 5 (maximum affected), where 1= very good, 2= good, 3= fair, 4= poor and 5= very poor. Higher scores indicate worse condition. Percentage of participants with at least 2 points improvement from baseline in PGA of osteoarthritis at specified weeks were reported.

    Measured: Baseline, Week 2, 4, 8, 12, 16

  12. Percentage of Participants With at Least 2 Points Improvement From Baseline in Patient Global Assessment (PGA) of Osteoarthritis: Last Observation Carried Forward (LOCF)

    Participants answered: "Considering all the ways the osteoarthritis in your index knee affects you, how are you doing today?" Participants responded on the scale ranging from 1 (minimum affected) to 5 (maximum affected), where 1= very good, 2= good, 3= fair, 4= poor and 5= very poor. Higher scores indicate worse condition. Percentage of participants with at least 2 points improvement from baseline in PGA of osteoarthritis at specified weeks were reported.

    Measured: Baseline, Week 2, 4, 8, 12, 16

  13. Percentage of Participants With Cumulative Reduction From Baseline up to Week 16 in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score: Baseline Observation Carried Forward (BOCF)

    WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms in participants with osteoarthritis of knee. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in the index knee during past 48 hours. It is calculated as mean of the scores from 5 individual questions scored on a numerical rating scale of 0 (minimum pain) to 10 (maximum pain), where higher scores indicate more pain. An overall possible WOMAC pain subscale score range is of 0 (minimum pain) to 10 (maximum pain), where higher scores indicate more pain. Percentage of participants with cumulative reduction (greater than 0 percent [%]; >= 10 %, 20 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 % and 90%; = 100 %) in WOMAC pain subscale from Baseline up to Week 16 were reported.

    Measured: Baseline up to Week 16

  14. Percentage of Participants With Cumulative Reduction From Baseline up to Week 16 in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score: Last Observation Carried Forward (LOCF)

    WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms in participants with osteoarthritis of knee. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in the index knee during past 48 hours. It is calculated as mean of the scores from 5 individual questions scored on a numerical rating scale of 0 (minimum pain) to 10 (maximum pain), where higher scores indicate more pain. An overall possible WOMAC pain subscale score range is of 0 (minimum pain) to 10 (maximum pain), where higher scores indicate more pain. Percentage of participants with cumulative reduction (greater than 0 percent [%]; >= 10 %, 20 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 % and 90%; = 100 %) in WOMAC pain subscale from Baseline up to Week 16 were reported.

    Measured: Baseline up to Week 16

  15. Change From Baseline for the Average Pain Score in the Index Knee at Week 2, 4, 8, 12 and 16: Baseline Observation Carried Forward (BOCF)

    Participants assessed daily average pain score in the index knee using a scale ranging from 0 (no pain) to 10 (maximum pain), where higher scores indicate more pain. A weekly mean was calculated using the daily average index knee pain scores within each specified study week.

    Measured: Baseline, Week 2, 4, 8, 12, 16

  16. Change From Baseline for the Average Pain Score in the Index Knee at Week 2, 4, 8, 12 and 16: Last Observation Carried Forward (LOCF)

    Participants assessed daily average pain score in the index knee using a scale ranging from 0 (no pain) to 10 (maximum pain), where higher scores indicate more pain. A weekly mean was calculated using the daily average index knee pain scores within each specified study week.

    Measured: Baseline, Week 2, 4, 8, 12, 16

  17. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale at Week 2, 4, 8, 12 and 16: Baseline Observation Carried Forward (BOCF)

    WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms in participants with osteoarthritis of knee. WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to osteoarthritis in knee joint during past 48 hours. It is calculated as mean of the scores from 2 individual questions each scored on numerical rating scale of 0 (minimum stiffness) to 10 (maximum stiffness), where higher scores indicate greater stiffness. An overall possible WOMAC stiffness subscale score range is of 0 (minimum stiffness) to 10 (maximum stiffness), where higher scores indicate higher stiffness. Stiffness is defined as a sensation of decreased ease in moving the index knee.

    Measured: Baseline, Week 2, 4, 8, 12, 16

  18. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale at Week 2, 4, 8, 12 and 16: Last Observation Carried Forward (LOCF)

    WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms in participants with osteoarthritis of knee. WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to osteoarthritis in knee joint during past 48 hours. It is calculated as mean of the scores from 2 individual questions each scored on numerical rating scale of 0 (minimum stiffness) to 10 (maximum stiffness), where higher scores indicate greater stiffness. An overall possible WOMAC stiffness subscale score range is of 0 (minimum stiffness) to 10 (maximum stiffness), where higher scores indicate higher stiffness. Stiffness is defined as a sensation of decreased ease in moving the index knee.

    Measured: Baseline, Week 2, 4, 8, 12, 16

  19. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Week 2, 4, 8, 12 and 16: Baseline Observation Carried Forward (BOCF)

    WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms in participants with osteoarthritis of knee. WOMAC pain subscale assess amount of pain experienced (score: 0 [minimum pain] to 10 [maximum pain], higher score = more pain), WOMAC physical function subscale assess degree of difficulty experienced (score: 0 [minimum difficulty] to 10 [maximum difficulty], higher score = higher difficulty) and WOMAC stiffness subscale assess the amount of stiffness experienced (score: 0 [minimum stiffness] to 10 [maximum stiffness], higher score = higher stiffness). WOMAC average score is the mean of WOMAC pain, physical function and stiffness subscale scores, giving an overall possible WOMAC average score range of 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicate worse response.

    Measured: Baseline, Week 2, 4, 8, 12, 16

  20. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Week 2, 4, 8, 12 and 16: Last Observation Carried Forward (LOCF)

    WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms in participants with osteoarthritis of knee. WOMAC pain subscale assess amount of pain experienced (score: 0 [minimum pain] to 10 [maximum pain], higher score = more pain), WOMAC physical function subscale assess degree of difficulty experienced (score: 0 [minimum difficulty] to 10 [maximum difficulty], higher score = higher difficulty) and WOMAC stiffness subscale assess the amount of stiffness experienced (score: 0 [minimum stiffness] to 10 [maximum stiffness], higher score = higher stiffness). WOMAC average score is the mean of WOMAC pain, physical function and stiffness subscale scores, giving an overall possible WOMAC average score range of 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicate worse response.

    Measured: Baseline, Week 2, 4, 8, 12, 16

  21. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score When Walking on a Flat Surface at Week 2, 4, 8, 12 and 16: Baseline Observation Carried Forward (BOCF)

    WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms in participants with osteoarthritis of knee. Participants responded by using a numerical rating scale of 0 (no pain) to 10 (maximum pain) about the amount of pain they experienced when walking on a flat surface, where 0= no pain and 10= extreme pain. Higher score indicates more pain.

    Measured: Baseline, Week 2, 4, 8, 12, 16

  22. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score When Walking on a Flat Surface at Week 2, 4, 8, 12 and 16: Last Observation Carried Forward (LOCF)

    WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms in participants with osteoarthritis of knee. Participants responded by using a numerical rating scale of 0 (no pain) to 10 (maximum pain) about the amount of pain they experienced when walking on a flat surface, where 0= no pain and 10= extreme pain. Higher score indicates more pain.

    Measured: Baseline, Week 2, 4, 8, 12, 16

  23. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score When Going Up or Down Stairs at Week 2, 4, 8, 12 and 16: Baseline Observation Carried Forward (BOCF)

    WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms in participants with osteoarthritis of knee. Participants responded by using a numerical rating scale of 0 (no pain) to 10 (maximum pain) about the amount of pain they experienced when going up or down stairs, where 0= no pain and 10= extreme pain. Higher score indicates more pain.

    Measured: Baseline, Week 2, 4, 8, 12, 16

  24. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score When Going Up or Down Stairs at Week 2, 4, 8, 12 and 16: Last Observation Carried Forward (LOCF)

    WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms in participants with osteoarthritis of knee. Participants responded by using a numerical rating scale of 0 (no pain) to 10 (maximum pain) about the amount of pain they experienced when going up or down stairs, where 0= no pain and 10= extreme pain. Higher score indicates more pain.

    Measured: Baseline, Week 2, 4, 8, 12, 16

  25. Change From Baseline in Short-Form 36 Health Survey (SF-36) 8 Health Domains, Mental Component Aggregate and Physical Component Aggregate Scores at Week 12 and 16: Baseline Observation Carried Forward (BOCF)

    SF-36 health survey is a self-administered questionnaire that measures each of the following 8 health domains: domain 1= general health, domain 2= physical function, domain 3= role physical, domain 4= bodily pain, domain 5= vitality, domain 6= social function, domain 7= role emotional and domain 8= mental health. Total score for each of the 8 domains are scaled from 0 (minimum level of functioning) to 100 (maximum level of functioning). These 8 domains are also summarized as 2 summary scores: mental component aggregate (MCA) and physical component aggregate (PCA). Total score range for each of the 2 summary scores =0 (minimum level of functioning) to 100 (maximum level of functioning). Higher (8 domains and 2 summary) scores indicate a better health related quality of life.

    Measured: Baseline, Week 12, 16

  26. Change From Baseline in Short-Form 36 Health Survey (SF-36) 8 Health Domains, Mental Component Aggregate and Physical Component Aggregate Scores at Week 12 and 16: Last Observation Carried Forward (LOCF)

    SF-36 health survey is a self-administered questionnaire that measures each of the following 8 health domains: domain 1= general health, domain 2= physical function, domain 3= role physical, domain 4= bodily pain, domain 5= vitality, domain 6= social function, domain 7= role emotional and domain 8= mental health. Total score for each of the 8 domains are scaled from 0 (minimum level of functioning) to 100 (maximum level of functioning). These 8 domains are also summarized as 2 summary scores: mental component aggregate (MCA) and physical component aggregate (PCA). Total score range for each of the 2 summary scores =0 (minimum level of functioning) to 100 (maximum level of functioning). Higher (8 domains and 2 summary) scores indicate a better health related quality of life.

    Measured: Baseline, Week 12, 16

  27. Time to Discontinuation Due to Lack of Efficacy

    Median time to discontinuation due to lack of efficacy was estimated using Kaplan-Meier method.

    Measured: Baseline up to Week 16

  28. Percentage of Participants Who Used Rescue Medication

    In case of inadequate pain relief for osteoarthritis, acetaminophen up to 4000 mg per day up to 3 days in a week could be taken as rescue medication. Percentage of participants with any use of rescue medication during the specified study week were summarized.

    Measured: Week 2, 4, 8, 12, 16

  29. Number of Days Participants Used Rescue Medication

    In case of inadequate pain relief for osteoarthritis, acetaminophen up to 4000 mg per day up to 3 days in a week could be taken as rescue medication. Number of days participants used any of the rescue medication, during the specified week were summarized.

    Measured: Week 2, 4, 8, 12, 16

  30. Amount of Rescue Medication Taken

    In case of inadequate pain relief for osteoarthritis, acetaminophen up to 4000 mg per day up to 3 days in a week could be taken as rescue medication. The total dosage of acetaminophen in mg used during the specified week were summarized.

    Measured: Week 2, 4, 8, 12, 16

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jan 2009 (estimated)
  2. Study start5 May 2009
  3. Primary completion17 May 2010
  4. Study completion31 Aug 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
832 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00830063
Sponsor's protocol ID
A4091015
Other IDs
P3 OA KNEE NSAID POPULATION
Status last verified
Apr 2021
First submitted
23 Jan 2009
Last updated
13 May 2021
Data monitoring committee
Yes
Individual data sharing
Yes: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.

Publications

  • Brown MT, Cornblath DR, Koltzenburg M, Gorson KC, Hickman A, Pixton GC, Gaitonde P, Viktrup L, West CR. Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis. Clin Drug Investig. 2023 Jul;43(7):551-563. doi: 10.1007/s40261-023-01286-3. Epub 2023 Jul 18.

    PubMed 37460782
  • Tive L, Bello AE, Radin D, Schnitzer TJ, Nguyen H, Brown MT, West CR. Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip. J Pain Res. 2019 Mar 19;12:975-995. doi: 10.2147/JPR.S191297. eCollection 2019.

    PubMed 30936738
  • Ekman EF, Gimbel JS, Bello AE, Smith MD, Keller DS, Annis KM, Brown MT, West CR, Verburg KM. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen. J Rheumatol. 2014 Nov;41(11):2249-59. doi: 10.3899/jrheum.131294. Epub 2014 Oct 1.

    PubMed 25274899

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing tanezumab 10 mg, tanezumab 5 mg and naproxen in people with Arthritis and Osteoarthritis, run by Pfizer at 94 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 May 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 94 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 13 May 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 16: Baseline Observation Carried Forward (BOCF) (time frame: Baseline (Day 1), Week 16). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00830063, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in